Henry Schein (HSIC)
NASDAQHealth CareMedical DistributionSnapshot 2026-07-07
$86.84+0.25%
Close 2026-07-07 · 1-day change
Reading HSIC? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track HSIC free→NASDAQHealth CareMedical DistributionSnapshot 2026-07-07
Reading HSIC? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track HSIC free→QuarterlyIQ Insights · HSIC
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. Current price $86.84. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $87 HSIC trades at 17× p/e, below its 27× p/e peer median. Our $91 fair value sits above the price. It's a high-confidence read. Analysts target $64–$100. Not investment advice.
$64.00 – $100.00 (median $85.00) · 5 analysts · as of 2026-06-11
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $4.91/sh owner earnings.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $85.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $62.04 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $46.72 | — | — | Hist. CAGR | high |
| graham number | 12M | $62.49 | — | — | TTM | high |
| Mgmt guidance | 12M | $140.98 | 26.6 | 5.30 | Mgmt | high |
| Peer EV/EBITDA | 12M | $93.79 | 15.3 | 8.04 | TTM | high |
| Peer P/FCF | 12M | $73.99 | 19.9 | 3.71 | TTM | high |
| Peer P/E | 12M | $136.72 | 26.6 | 5.14 | TTM | high |
| Peer P/S | 12M | $380.47 | 3.3 | 115.32 | TTM | high |
| PEG | 12M | $142.18 | 27.7 | 5.14 | TTM | high |
| residual income | 12M | $43.32 | — | — | TTM | high |
| Own P/E history | 12M | $86.43 | 16.8 | 5.14 | TTM | high |
| triangulated | 12M | $138.21 | 26.6 | 5.20 | Triangulated | high |
| Mgmt guidance | 3Y | $187.36 | 26.6 | 7.04 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $74.51 | 19.9 | 3.74 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $168.71 | 26.6 | 6.34 | Analyst | medium |
| Peer P/S | 3Y | $434.74 | 3.3 | 131.77 | guidance | medium |
| PEG | 3Y | $175.44 | 27.7 | 6.34 | Analyst | medium |
| Own P/E history | 3Y | $106.65 | 16.8 | 6.34 | Analyst | medium |
| Mgmt guidance | 5Y | $226.48 | 26.6 | 8.51 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $74.86 | 19.9 | 3.76 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $184.23 | 26.6 | 6.93 | Analyst | high |
| Peer P/S | 5Y | $474.75 | 3.3 | 143.89 | guidance | high |
| PEG | 5Y | $191.59 | 27.7 | 6.93 | Analyst | high |
| Own P/E history | 5Y | $116.46 | 16.8 | 6.93 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.